Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (NASDAQ: DRIO) has secured a $50 million senior secured term loan facility from OrbiMed, enhancing its financial stability. The initial $25 million is available immediately, with another $25 million contingent on achieving revenue thresholds by June 30, 2023. This funding aims to support DarioHealth's digital therapeutics platform, especially in chronic disease management. The company now potentially has over $100 million in capital access, allowing it to invest in its growing B2B market segment without needing further capital raises.

DarioHealth Corp. (Nasdaq: DRIO) highlighted breakthroughs in chronic condition management at the American Diabetes Association's 82nd Scientific Sessions on June 3-7, 2022. Three studies revealed significant enhancements in glucose control and reductions in blood pressure for users facing diabetes and hypertension. Key findings include:

• Two-thirds of users improved systolic blood pressure by 13 mmHg.
• High-risk Type 2 diabetes users reduced blood glucose by 15%.
• Average blood glucose decreased by 14%-15% across diverse ethnicities.

The integrated solutions demonstrate Dario's potential to transform chronic condition management.

DarioHealth Corp. (NASDAQ: DRIO) announced two new contracts to provide digital therapeutic solutions to a national employer and a provider group, effective Q3 2022. The Texas-based employer will implement digital behavioral health support for employees across 17 states, while the provider group will utilize Dario's integrated metabolic solutions for diabetes and weight management. These contracts are expected to enhance Dario's revenue growth in 2022, aligning with their strategy to expand their client base and personalized health solutions.

DarioHealth Corp. (Nasdaq: DRIO) reported a strong Q1 2022, posting revenues of $8.06 million, a 124% increase year-over-year and a 34% rise sequentially. Gross margins expanded to 49.4% (GAAP) and 61% (non-GAAP). The company added 14 new B2B accounts, including two health plans, and secured a $30 million agreement with Sanofi to enhance its market outreach. Despite an operating loss of $15.9 million, DarioHealth improved its financial position by reducing operating costs and marketing expenses, indicating a positive trend in its B2B transformation.

DarioHealth Corp. (Nasdaq: DRIO) will announce its financial results for Q1 2022 on May 12, 2022, hosting a conference call and webcast at 8:30 am ET. Key executives, including CEO Erez Raphael, will lead the discussion. Interested participants can join via dial-in or the provided webcast link. A replay will be available after the call until June 12, 2022. DarioHealth specializes in digital therapeutics for chronic conditions, offering an innovative platform that integrates multiple health solutions.

DarioHealth Corp. (Nasdaq: DRIO) showcased a study at the ATTD Conference revealing effective diabetes and weight management outcomes via its integrated digital therapeutics platform. Analyzing data from 715 individuals, nearly two-thirds reduced their BMI by an average of 2.8 units and achieved a 7.4% weight loss. A subgroup with high-risk blood glucose levels experienced a 4.9% weight loss and a 16.1% reduction in blood glucose over 12 months. This study underscores Dario’s holistic approach, which could significantly impact chronic condition management.

DarioHealth Corp. (Nasdaq: DRIO) has announced a partnership with Colorado Access, the largest public sector health plan in Colorado, to enhance digital chronic condition management for underserved populations. Starting in Q2 2022, Dario will provide integrated solutions for members managing diabetes, hypertension, weight, and behavioral health needs. This collaboration aims to deliver personalized care using Dario's comprehensive digital therapeutics platform, combining tools, devices, and coaching. The partnership reflects a growing recognition of the importance of digital health in improving member outcomes.

DarioHealth Corp. (Nasdaq: DRIO) reported a substantial revenue increase of 171%, reaching $20.5 million for 2021, driven by its B2B growth and acquisitions. The fourth quarter saw a revenue rise to $6.03 million, a 190% year-on-year increase. However, gross profit as a percentage declined to 9.1%. Operating expenses surged to $22.2 million, leading to an operating loss of $21.7 million. A notable collaboration with Sanofi aims to enhance market presence. Cash reserves stood at $35.8 million, supplemented by a $40 million raise in March 2022 to support ongoing strategic initiatives.